Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More

MENU

Weekly Outpatient Palliative Care Interventions Favored by Head and Neck Cancer Patients

July 23, 2021

Dr. Jessica R. Bauman, chief of the Division of Head and Neck Medical Oncology, headed the studyDr. Jessica R. Bauman, chief of the Division of Head and Neck Medical Oncology, headed the study

PHILADELPHIA (July 23, 2021)—Over 90% of head and neck cancer patients found weekly palliative care visits to be a valuable addition to their treatment, a recent study conducted at Fox Chase Cancer Center has concluded.

Although palliative care is known to improve symptoms and coping in patients with advanced cancer, it hasn’t been evaluated for head and neck cancer (HNC) patients receiving curative-intent outpatient chemoradiation therapy at a single care delivery site. Chemoradiation for HNC is one of the most challenging treatments for patients due to significant side effects, so incorporating better supportive care during treatment is critical.

Jessica R. Bauman, MD, chief of the Division of Head and Neck Medical Oncology and assistant professor in the Department of Hematology/Oncology at Fox Chase, headed the study. Carolyn Y. Fang, PhD, professor in the Cancer Prevention and Control Program and associate director for Population Science, and Areej El-Jawahri, MD, associate director of the Cancer Outcomes Research and Education Program at Massachusetts General Hospital, served as mentors on the research. The pilot study was funded by the Palliative Care Research Cooperative Group. 

Weekly palliative care visits with a focus on symptom management and coping were integrated with oncology care for the study. Palliative care nurses provided the weekly palliative care visits; they were supported by palliative care nurse practitioners and palliative medicine physicians where necessary.

A post-intervention satisfaction survey was conducted to assess acceptability, symptom burden, mood, and quality of life. Ninety-five percent of patients found the one-on-one format of the intervention and the opportunity to receive additional care “very helpful” and would “definitely recommend” it.

“Adding an extra layer of support during very challenging treatment with incorporating a palliative care team into outpatient care” for these patients has never been studied, Bauman said. 

“We received favorable preliminary data with this pilot study. Now it’s important to study a larger, randomized group of patients to determine how the intervention affects outcomes,” which could help convince healthcare systems to invest in such strategies, she added.

Bauman said she would like to address other questions in a larger study, including whether such interventions can lessen the burden of symptoms and improve mood, and whether the palliative care intervention decreases hospitalizations, thus improving overall care.

“It’s imperative that we deliver the best treatment and care. At the same time, we need to provide the whole patient with support. We want patients to survive and thrive,” Bauman said.

The paper, “A Pilot Study of a Collaborative Palliative and Oncology Care Intervention for Patients With Head and Neck Cancer,” was published in the Journal of Palliative Medicine. 

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase